Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

COMPLETED
Phase Ib Study of SC Milatuzumab in SLE
Description

Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).

TERMINATED
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Description

The purpose of this study it to determine whether the use of a gonadotropin releasing hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with rheumatic diseases will provide greater ovarian protection than placebo.